checkAd

     116  0 Kommentare VBI Vaccines Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting - Seite 3

    Lesen Sie auch


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    Seite 3 von 3

    VBI Vaccines Announces Upcoming Poster Presentation of Phase 1/2a data of VBI-1901 in Recurrent GBM Patients at AACR Virtual Annual Meeting - Seite 3 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that expanded immunologic and tumor response data from the ongoing Phase …